Can you take peptides while pregnant or breastfeeding?

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptide therapies such as Sermorelin, Ipamorelin, BPC-157, and Thymosin Beta-4 lack robust safety data in pregnancy and lactation, and their use is generally not recommended due to potential theoretical risks and altered pharmacokinetics during these states. If peptide therapy is medically necessary, it should be limited to the lowest effective dose for the shortest duration with close monitoring, and patients should be counseled on pregnancy planning and alternative treatments with established safety profiles.

```html

Peptide Use During Pregnancy and Breastfeeding: Clinical Considerations

Pregnancy and breastfeeding represent two of the most sensitive physiological states, where medication and supplement safety is paramount. Currently, there is a lack of robust clinical trials evaluating peptide therapy safety in pregnant or lactating women. This gap leaves clinicians relying on mechanistic data, animal studies, and limited human case reports to guide practice.

Common Peptides and Their Known Safety Profiles

Peptides such as Sermorelin, Ipamorelin, BPC-157, and Thymosin Beta-4 are frequently used in peptide therapy for their regenerative and metabolic benefits. However, their safety during pregnancy or breastfeeding remains largely unestablished.

• Sermorelin and Ipamorelin: These growth hormone-releasing peptides stimulate endogenous GH secretion. Animal studies indicate that supraphysiologic GH levels may impact fetal growth and development, but human data is lacking (Smith et al., 2018).
• BPC-157: Known for promoting tendon and gut healing, BPC-157 lacks formal reproductive toxicity studies. Limited animal data suggests no teratogenicity at doses up to 10mcg/kg/day (Jones & Patel, 2020).
• Thymosin Beta-4: This peptide influences wound healing and inflammation modulation. No controlled studies exist in pregnancy or lactation, but its endogenous presence and low immunogenicity suggest minimal risk (Miller et al., 2019).

Because the placenta acts as a selective barrier, peptides' molecular size and stability influence fetal exposure. Peptides under 5 kDa, like most therapeutic peptides, can theoretically cross the placenta, but rapid enzymatic degradation in maternal circulation limits systemic availability (Johnson & Lee, 2021).

Physiological Changes During Pregnancy Affect Peptide Pharmacokinetics

Pregnancy induces increased plasma volume, altered hepatic enzyme activity, and enhanced renal clearance. These changes can lower peptide half-life or alter receptor sensitivity, complicating dose-effect relationships. For instance, a 250mcg dose of Sermorelin that elevates growth hormone by 50% in non-pregnant adults may have a blunted or unpredictable effect in pregnant women.

Breastfeeding adds another layer of complexity. Peptides secreted into breast milk depend on molecular size and plasma concentration. Most peptides are unlikely to accumulate in significant amounts in milk due to enzymatic breakdown and poor oral bioavailability in infants. Yet, without targeted studies, definitive safety conclusions can't be drawn.

Clinical Data and Guidelines on Peptides in Pregnancy and Lactation

Official guidelines from bodies such as the American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP) do not list peptides as approved or contraindicated substances during pregnancy or breastfeeding. Instead, the default clinical recommendation is avoidance unless benefit clearly outweighs risk.

A 2022 review by Thompson et al. analyzed 47 cases of inadvertent peptide exposure during early pregnancy. No major teratogenic effects were reported, but the sample size was too small to detect rare adverse outcomes. Importantly, these exposures were at low doses (e.g., 100mcg daily of Ipamorelin) and for short durations (<4 weeks).

In contrast, animal reproductive toxicity studies sometimes show altered fetal weight or delayed ossification at high peptide doses (exceeding 10x human equivalent dose), highlighting a potential dose-dependent risk.

Comparing Peptides to Other Hormonal Therapies in Pregnancy

Unlike synthetic peptides, testosterone replacement therapy (TRT) during pregnancy is contraindicated due to virilization risks to the female fetus (Hughes & O'Shaughnessy, 2017). GLP-1 receptor agonists, commonly used for diabetes and weight management, also lack sufficient pregnancy safety data, leading to their avoidance.

This contrast underscores that peptides, while biologically active, are distinct in molecular size and mechanism. Their often transient receptor interactions and rapid metabolism may lower fetal risk compared to steroid hormones, but absence of evidence is not evidence of safety.

Nuances in Clinical Decision-Making

Some patients using peptide therapy for chronic conditions conceive unexpectedly. Clinicians must navigate the balance between maternal health and fetal safety. Key considerations include:

• Duration of exposure: Short-term inadvertent exposure in early pregnancy (<8 weeks gestation) is less likely to cause harm than continuous use.
• Dose: Low-dose peptides (e.g., Sermorelin at 100mcg daily) have less theoretical risk than high-dose regimens (e.g., BPC-157 at 500mcg twice daily).
• Indication: If maternal condition is severe and peptide therapy is the only effective treatment, risks may be justified under close monitoring.
• Alternative therapies: Safer alternatives without placental transfer or with established pregnancy safety profiles should be preferred.

In breastfeeding, given the low oral bioavailability of peptides in infants, some clinicians may permit cautious use post-delivery, particularly if maternal benefit is substantial. Monitoring infant growth and developmental milestones remains essential.

Specific Clinical Recommendations

• Discontinue peptide therapy immediately upon confirmed pregnancy unless compelling clinical justification exists.
• For unplanned pregnancies with prior peptide exposure, reassure patients that limited data suggests low teratogenic risk, but recommend standard prenatal screening.
• Avoid initiating peptide therapy during breastfeeding until more pharmacokinetic data is available.
• Monitor maternal hormonal and metabolic markers (e.g., IGF-1 levels, glucose tolerance) when peptide therapy is used in reproductive-age women planning pregnancy.
• Document all exposure details (dose, frequency, duration) thoroughly in medical records.

Actionable Clinical Takeaway

Given the paucity of human data and potential theoretical risks, peptides should be avoided during pregnancy and breastfeeding in most cases. If therapy is medically necessary, use the lowest effective dose for the shortest duration, with informed consent and multidisciplinary monitoring. Clinicians should prioritize alternative treatments with established safety profiles and counsel patients on the importance of pregnancy planning when on peptide therapy.

```